291 related articles for article (PubMed ID: 15633398)
21. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
22. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
24. Concurrent end-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy.
Graham PH; Clark C; Abell F; Browne L; Capp A; Clingan P; De Sousa P; Fox C; Links M
Australas Radiol; 2006 Aug; 50(4):342-8. PubMed ID: 16884421
[TBL] [Abstract][Full Text] [Related]
25. [Multimodal therapy of small cell and non-small cell lung carcinoma].
Serke M; Kollmeier J
Dtsch Med Wochenschr; 2007 Jun; 132(22):1221-4. PubMed ID: 17520508
[TBL] [Abstract][Full Text] [Related]
26. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
27. [Future of immunologic therapy of bronchogenic carcinoma].
Saviano G; Borrelli G; Cerbone V; La Gala F; Ferrara P
Arch Monaldi Mal Torace; 1990; 45(5):395-9. PubMed ID: 1726851
[TBL] [Abstract][Full Text] [Related]
28. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
29. [Which chemotherapy for diffuse forms of small-cell cancers?].
Pujol JL; Quantin X; Carestia L; Guyot V; Khial F
Rev Mal Respir; 1999 Jan; 16 Suppl 3():S149-55. PubMed ID: 10088297
[No Abstract] [Full Text] [Related]
30. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
[TBL] [Abstract][Full Text] [Related]
31. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
32. [Stage IIIB non-small cell lung cancer. Is there a recommended treatment? ].
Fournel P
Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S54-16S60. PubMed ID: 17268337
[TBL] [Abstract][Full Text] [Related]
33. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
34. [Chemotherapy of bronchial carcinoma].
Wolf M; Havemann K
Chirurg; 1990 Aug; 61(8):571-7. PubMed ID: 2171884
[No Abstract] [Full Text] [Related]
35. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
36. Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
Green MR
J Clin Oncol; 2008 Jul; 26(19):3112-3. PubMed ID: 18591551
[No Abstract] [Full Text] [Related]
37. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer.
Iranzo V; Bremnes RM; Almendros P; Gavilá J; Blasco A; Sirera R; Camps C
Lung Cancer; 2009 Jan; 63(1):63-7. PubMed ID: 18550204
[TBL] [Abstract][Full Text] [Related]
39. [Clinical study of the secondary toxicity, effective responses and survival time in the treatment of primary non-microcytic (NSCLC) carcinoma of the lung with various polychemotherapy regimens].
Carminati F; Maccone C; De Marinis F
Clin Ter; 1982 May; 101(3):221-7. PubMed ID: 6284434
[No Abstract] [Full Text] [Related]
40. Small cell bronchogenic carcinoma: a distinct clinicopathologic entity.
Cohen MH; Matthews MJ
Semin Oncol; 1978 Sep; 5(3):234-43. PubMed ID: 211637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
